KCNA1抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Human brain malignant glioma tissue, Primary antibody: P10984(KCNA1 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P10984(KCNA1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

KCNA1 antibodies target the KCNA1 protein, a voltage-gated potassium channel (Kv1.1) encoded by the *KCNA1* gene. This channel is critical for regulating neuronal excitability, particularly in the central and peripheral nervous systems, where it stabilizes membrane potential and controls action potential repolarization. Antibodies against KCNA1 are primarily associated with autoimmune neurological disorders, such as autoimmune encephalitis, neuromyotonia, and Morvan syndrome. These autoantibodies disrupt potassium channel function, leading to hyperexcitability of neurons, which manifests as muscle stiffness, cramps, myokymia, autonomic dysfunction, or encephalopathic features like seizures and cognitive deficits.

KCNA1 autoimmunity is often paraneoplastic, linked to thymomas or small-cell lung cancer, but idiopathic cases also occur. Diagnosis involves detecting antibodies in serum or cerebrospinal fluid (CSF) using cell-based assays (CBAs), immunohistochemistry, or Western blot. Clinically, KCNA1 antibody-associated syndromes overlap with other potassium channelopathies (e.g., LGI1/CASPR2 antibodies), necessitating comprehensive testing. Early immunotherapy (steroids, IVIG, plasma exchange) often improves outcomes, highlighting the importance of timely recognition. Research continues to explore the exact pathogenic mechanisms and broader associations of these antibodies in autoimmune neurology.